Podcast: Ep#101 Omega-3 Industry on The Rise With Algae Farming (ft. Dr Graeme Barnett, CEO & MD of Qponics)
(Audio player not working? Head to our Soundcloud page to listen to all our podcasts.)
Today on Eden Exchanges we spoke to Dr Graeme Barnett, CEO and Managing Director of Qponics Limited, an algae Omega-3 producing company based in Australia, working together with BlueMount Capital.
Graeme has a background in microbiology with vast experience from the industry which led him to found Qponics and looking into algae as a new source of omega-3.
Medical microbiologist from New Zealand wanting to take his knowledge further
Future of developing large scale algae pond methods
Interest and kick start into the business and industry
- Algae farming
Technology and benefits
Differences between algae and other sources
- Main market and demand
EPA omega-3 has high demand in Europe, North America and Asia
- Market response
Interest has been high with several years of enquiries
- Geographic areas
Why Australia is such a beneficial location
- Excellent climate
Allowing production 12 months of the year
- Management team and board in place
Vast experience in the general field of the company
Demand outstrips supply and demand remains high for quality products, such as EPA omega-3
- Drives and goals for the future
Create a sustainable business, no huge amounts of waste products with residual containing high protein bio mass
- Be a part of Qponic’s future
How to get involved with the business
- How to get in touch
How to contact Graeme or a member of the team from BlueMount Capital
About Qponics Limited
Qponics is an agricultural company operating in the agri-technology, food and nutraceutical sectors based in Brisbane, Australia. The Qponics team is excited about the prospect of entering the rapidly growing wholesale omega-3 essential oils market at a time when the traditional marine animal sources supply chain is becoming constrained and uncertain as many fish species are in global decline.
Qponics is focused on the sustainable and organic production of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) omega-3 oils, high protein algal biomass and many other high-value products from Australian strains of algae. EPA and DHA are essential fatty acids not synthesised by the body. Many neurological, cardiovascular and degenerative diseases may arise from diets low in EPA and DHA. The product will be ideal for consumption by vegetarians, vegans and the broader consumer community.
DISCLAIMER: Eden Exchange Pty Ltd and BlueMount Capital (QLD) Pty Ltd have taken all reasonable care in publishing the information contained in this Director Briefing Podcast. It is information given in a summary form and does not purport to be complete. The information contained is not intended to be used as the basis for making any investment decision and you are solely responsible for any use you choose to make of the information. We strongly advise that you seek independent professional advice before making any investment decisions. Eden Exchange Pty Ltd and BlueMount Capital (QLD) Pty Ltd are not responsible for any consequences of the use you make of the information, including any loss or damage you or a third party might suffer as a result of that use.
For previous Director Briefings or to receive future Director Briefings and Podcasts, visit Eden Exchange’s Director Briefing Service or phone +613 8658 2292.